A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis

Trial Profile

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms QUARTZ II-III
  • Sponsors AbbVie
  • Most Recent Events

    • 18 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 20 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
    • 20 May 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top